Privi Speciality Chemicals Ltd

- The company has indicated that about 70% of their business for the financial year is already contracted. - There is strong ongoing demand for their products, which are essential FMCG items used daily (shower, washing clothes, brushing teeth). - They have a sustained demand outlook with no major customer delays expected in the near to medium term. - The company emphasizes a stable and positive growth trajectory based on current order backlog. - The products cater to large F&F industry customers (top 15 globally), facilitating easier commercialization of new products. - Capacity expansions and de-bottlenecking efforts are underway to meet growing demand, suggesting the order book is expected to be robust. - Orders are globally diversified, with about 70% exports. - No specific quantitative details on exact orderbook size were disclosed in the call.

- The company targets a revenue of Rs. 5,000 crores and an EBITDA of around Rs. 1,000 crores within the next 3-4 years. - Annual growth guidance is about 20%, consistent with past performance. - Capacity expansions, including converting plants to continuous production and augmentation, are underway to support growth and meet demand. - Several new specialty aroma chemicals have been developed at lab and pilot levels, expected to drive future growth post the current capacity expansion slated for completion by March 2026. - The company aims to maintain EBITDA margins around 20-22% over the coming years. - Efforts are in progress to reduce net working capital days from about 140 to 120-125 to improve operational efficiency. - Overall, sustained strong demand, especially from FMCG sectors and stable contracted business (about 70%), supports optimistic growth prospects.

- The company targets sustained growth with a vision to achieve Rs. 5,000 crore revenue and Rs. 1,000 crore EBITDA in 3-4 years, implying ~20%+ EBITDA margins. (Page 12) - EBITDA margins have shown strength at ~22% currently and are expected to be sustainable going forward. (Page 15) - Capacity expansions and process debottlenecking are underway which will support continued volume and margin growth. (Pages 7, 14) - New specialty products from by-product streams and innovations at lab & pilot scale will drive future margin expansions and revenue growth. (Pages 13,14) - The firm expects gross margins (RMC costs) to stay stable at ~53-57%, with cost savings supporting EBITDA margin expansion. (Page 16) - Operational efficiencies like plant automation and continuous processing contribute positively to profitability. (Page 7) - The company aims to reduce net working capital days to 120-125 to improve cash flow. (Page 13) - Overall, management is confident of maintaining >20% EBITDA margins and 20%+ annual growth over next 3-5 years.

- The company plans a significant CAPEX of about Rs. 1,100 crores over the next 2-3 years to support growth and capacity expansion. - Fundraising for this CAPEX will primarily be through a mix of internal accruals and bank debt. - Equity infusion is currently not favored due to its higher cost; hence, the company prefers debt and internal accruals. - There is no explicit mention of a new equity fundraising round in the near future. - The company aims to keep leverage at manageable levels and avoid becoming highly leveraged.

- Total planned CAPEX to achieve the 5,000 crore revenue and 1,000 crore EBITDA vision is around Rs. 1,100 crores over the next few years. - The first phase of CAPEX is underway with about Rs. 280-300 crores invested, expected to complete by year-end, enabling 20% growth over the next couple of years. - Applications for environment clearances are in process for phases II and III to support further expansion. - Additional CAPEX includes Rs. 400 crores (approx.) planned for Privi Fine Sciences, with further investments expected mainly in the Lote plant. - Funding for CAPEX will be a mix of internal accruals and debt, with minimal reliance on equity. - Strategic focus on new and game-changing renewable route products supporting future growth and margin improvement.